Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention.
about
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromesPeri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.What is the incidence of myocardial necrosis in elective patients discharged on the same day following percutaneous coronary intervention?Predictors and Periprocedural Myocardial Injury Rate of Small Side Branches Occlusion in Coronary Bifurcation Intervention.Clinical and Functional Outcomes Associated With Myocardial Injury After Transfemoral and Transapical Transcatheter Aortic Valve Replacement: A Subanalysis From the PARTNER Trial (Placement of Aortic Transcatheter Valves).Peri-procedural myocardial injury: 2005 update.Effect of rosuvastatin dose-loading on serum sLox-1, hs-CRP, and postoperative prognosis in diabetic patients with acute coronary syndromes undergoing selected percutaneous coronary intervention (PCI).Rise of serum troponin levels following uncomplicated elective percutaneous coronary interventions in patients without clinical and procedural signs suggestive of myocardial necrosisCurrent update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.Sensory-sympathetic coupling in superior cervical ganglia after myocardial ischemic injury facilitates sympathoexcitatory action via P2X7 receptor.Efficacy of coronary revascularization in patients with acute chest pain managed in a chest pain unitPercutaneous coronary interventions and statins therapy.Elevated preoperative HMGB1 as predictor of myocardial injury post-percutaneous coronary intervention.A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions.Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).Percutaneous coronary intervention in treatment of multivessel coronary artery disease in patients with non-ST-segment elevation acute coronary syndromeMyocardial ischemia is a key factor in the management of stable coronary artery diseaseStents and statins: history, clinical outcomes and mechanisms.Effect of statins therapy prior to percutaneous coronary intervention.Prognostic value of creatine kinase-myocardial band isoenzyme elevation following percutaneous coronary intervention: a meta-analysis.Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials.High dose statin loading prior to percutaneous coronary intervention decreases cardiovascular events: a meta-analysis of randomized controlled trials.Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor α1 in cardiac repair.Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention According to Timing of Infusion: Insights From the SELECT-ACS Trial.Myocardial protection from ischemia-reperfusion injury post coronary revascularization.Effect of High-Dose Statin Pretreatment on the Incidence of Periprocedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: Grading the Evidence Through a Cumulative Meta-analysis.Risk stratification of periprocedural myocardial infarction after percutaneous coronary intervention: Analysis based on the SCAI definition.Association of periprocedural myocardial infarction with long-term survival in patients treated with coronary revascularization therapy of chronic total occlusion.Preprocedural N-terminal pro-B-type natriuretic peptide as a useful marker for predicting periprocedural myocardial injury following percutaneous coronary intervention in diabetic patients without cardiac dysfunction.Measurement and prevention of myocardial injury during percutaneous coronary intervention.Procedure-related myonecrosis after bare and drug-eluting stent implantation.Elevated CK-MB values after routine angioplasty predicts worse long-term prognosis in low-risk patients.Association of baseline C-reactive protein levels with periprocedural myocardial injury in patients undergoing percutaneous bifurcation intervention: a CACTUS study subanalysis.Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis.Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.Impact of metabolic syndrome on myocardial injury and clinical outcome after percutaneous coronary intervention.Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study.Elevation of biomarkers and long-term outcome after percutaneous coronary intervention.
P2860
Q28199725-DBD95BC6-C633-4C9C-8E85-A877DF0B1293Q34147112-20EB935A-F25B-43FD-BB3F-DDD147D9F10CQ35583201-893E3586-17B9-49DD-A601-1EB7F55EAD02Q35858267-76EA7D7E-464A-430E-9C5D-0DBD0266A6FDQ36219512-D28A5371-D35A-4429-847D-69859E94B570Q36263844-EBEA2832-3CA3-4C64-810F-36952567CFFAQ36493187-8FED865E-2BE1-46D2-B956-EB1C084960DEQ36649949-FAF76104-4459-44E0-9B92-544A75262F5FQ37076393-839CBCEF-5A9F-4A25-A90A-C29E6FB4D74DQ37131969-F3342C42-2310-4C5A-9D30-4DF74DE9D6FAQ37151370-2ECE93B6-EE6F-41E8-B0C5-109B1442D799Q37362723-10BD8B7B-29EB-490E-A354-4190E5115A4DQ37432890-3066332E-7B18-4F32-83F3-1766C477B117Q37438436-A6F5AAB1-214D-42EF-984D-5DDC794DDC2AQ37472971-6C7A3221-6134-4B85-8973-9B1698571C4BQ37561885-4B1D6666-BAD8-44AF-9CE4-05EF455F5CB5Q37722766-C13009B9-71D9-47FE-9A12-FC2FF2CFEE10Q37786646-1275E136-38DD-4358-A21D-04307F36F898Q37976137-DD7681CC-6801-42D5-845A-CC06D350D3EDQ38022548-98FAF233-00A1-49DD-9315-A59BF4D9D771Q38137864-7394303C-CF5F-471E-85C3-76FE3401046CQ38165881-1E56FDC8-FF2E-4F3B-A733-EE433561B877Q38287099-F7BFD3CC-7B5B-468A-9B7F-8CA4D1E9D920Q38384596-377280B2-F021-4A34-8868-202403C0BC36Q38552442-04CC50C0-FCBE-40E2-95C8-CD3012335D0CQ38600680-E330223B-BA7B-4793-AE00-C96A0FFBFE10Q40338622-51271DCC-8E28-4EE5-8CC3-EFD8034FAA94Q40366019-3FA974F5-CB05-46C2-8BF1-02A8AD0221B1Q40704357-B51BFFDC-1A2E-4DD4-920E-F0C0BE5125CCQ42409828-FCA8363A-F4E0-4E27-B12F-C4F284486D1FQ43046171-F8C7E051-3A4D-4BA1-A9AA-2BE28E26AE2DQ43294342-74ED2ECA-44E1-4FBE-856B-E16E9FA5EAD1Q43505647-AFBBDFDF-1074-4880-933D-C6C65AA9FB31Q43722133-0D7B9972-4F9B-4290-9BBF-233F0D5B1E4EQ43740908-5B5EA4A2-F1D3-4E70-93CB-7673834D5CDFQ43812550-6FB6FA82-0164-4A79-B9F7-85CA7B9A9AF4Q44936093-967891CF-1B04-4A1E-8CD5-880140795F52Q45839848-DD4A18B1-2957-40D5-88C8-DEBC8459E55BQ45917470-5FE5720D-17C4-4413-9FA7-6DDCB86BC8A8Q46472607-47BD5C9E-C7A7-4CFE-A264-2F6F1B44B0DE
P2860
Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Mortality risk conferred by sm ...... taneous coronary intervention.
@en
Mortality risk conferred by sm ...... taneous coronary intervention.
@nl
type
label
Mortality risk conferred by sm ...... taneous coronary intervention.
@en
Mortality risk conferred by sm ...... taneous coronary intervention.
@nl
prefLabel
Mortality risk conferred by sm ...... taneous coronary intervention.
@en
Mortality risk conferred by sm ...... taneous coronary intervention.
@nl
P1476
Mortality risk conferred by sm ...... taneous coronary intervention.
@en
P2093
Demosthenes G Katritsis
Evangelia Karvouni
P304
P356
10.1016/S0735-1097(03)01044-1
P407
P577
2003-10-01T00:00:00Z